Takashi, K., Takane, K., Hideyuki, S., Hidetsugu, N., Kenzo, Y., Hidehiko, K., et al. (2005) Effective production of 3,4-dihydroxyphenyl-L-alanine (L-DOPA) with Erwinia herbicola cells carrying a mutant transcriptional regulator TyrR. Journal of Biotechnology, 115, 303-306. doi:10.1016/j.jbiotec.2004.08.016

has been cited by the following article:

• TITLE: Biological sources of L-DOPA: An alternative approach

  AUTHORS: Sushama A. Patil, Onkar A. Apine, Shripad N. Surwase, Jyoti P. Jadhav

  KEYWORDS: Parkinson’s Disease; L-DOPA; Biological Sources

  JOURNAL NAME: Advances in Parkinson's Disease, Vol.2 No.3, July 19, 2013

  ABSTRACT: Parkinson’s disease was first formally identified by British physician James Parkinson in 1817 as “The Shaking Palsy”. L-DOPA (3,4-dihydroxy-phenyl-L-alanine) has been considered as a gold-standard treatment for Parkinson’s disease. The world market for L-DOPA is about 250 t/year and the total market volume is about $101 billion per year. The present review summarizes the different biological sources for the production of L-DOPA. The process for L-DOPA production from different biological sources has advantages over the chemical methods such as, enantiometrically pure L-DOPA, less incubation time and cost effective method. L-DOPA is found naturally in certain plant foods, particularly broad beans which found to replenish brain levels of L-DOPA even more quickly, and for longer periods, than conventional medication.